Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality
- First Posted Date
- 2003-07-18
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 148
- Registration Number
- NCT00065156
- Locations
- πΊπΈ
Arizona Cancer Center, Tucson, Arizona, United States
πΊπΈDesert Hematology & Oncology Medical Group, Rancho Mirage, California, United States
πΊπΈMayo Clinic, Rochester, Minnesota, United States
Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes
- First Posted Date
- 2003-07-17
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 215
- Registration Number
- NCT00064974
- Locations
- πΊπΈ
Alta Bates Cancer Center, Berkeley, California, United States
πΊπΈMidwest Cancer Research Group, Skokie, Illinois, United States
πΊπΈThe Cleveland Clinic Foundation, Cleveland, Ohio, United States
A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Drug: A (Thalidomide + Dexamethasone)Drug: B (Placebo + Dexamethasone)
- First Posted Date
- 2003-04-08
- Last Posted Date
- 2015-09-11
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 470
- Registration Number
- NCT00057564
- Locations
- πΊπΈ
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
πΊπΈClinical Research Consultants, Inc., Hoover, Alabama, United States
πΊπΈArizona Clinical Research Center, Tucson, Arizona, United States
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
- Conditions
- MelanomaNeoplasm Metastasis
- First Posted Date
- 2003-04-08
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 274
- Registration Number
- NCT00057616
- Locations
- π¦πΊ
Royal Newcastle Hospital, Newcastle, New South Wales, Australia
π¦πΊWestmead Hospital, Westmead, New South Wales, Australia
π¦πΊRoyal Hobart Hospital, Hobart, Tasmania, Australia
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 353
- Registration Number
- NCT00056160
- Locations
- πΊπΈ
Ohio State University, Columbus, Ohio, United States
πΊπΈMD Anderson Cancer Center, Houston, Texas, United States
πΊπΈClinical Research Consultants, Inc., Hoover, Alabama, United States
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma
- Conditions
- MelanomaNeoplasm Metastasis
- First Posted Date
- 2003-03-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 274
- Registration Number
- NCT00055562
- Locations
- πΊπΈ
UPMC Cancer Pavillion, Pittsburgh, Pennsylvania, United States
π¨π¦Princess Margaret Hospital, Toronto, Ontario, Canada
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2003-01-07
- Last Posted Date
- 2009-09-23
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 100
- Registration Number
- NCT00051116
- Locations
- πΊπΈ
Myeloma Institute University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes
- Conditions
- Myelodysplastic Syndromes
- First Posted Date
- 2002-12-24
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 220
- Registration Number
- NCT00050843
- Locations
- πΊπΈ
Beaumont Cancer Center, Royal Oak, Michigan, United States
πΊπΈTexas Oncology PA-BMT Center, Dallas, Texas, United States
πΊπΈNorthwest Medical Specialists, Arlington Heights, Illinois, United States
D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients
- Conditions
- FatigueNeoplasms
- First Posted Date
- 2002-10-09
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 160
- Registration Number
- NCT00047476
- Locations
- πΊπΈ
Clinical Trials and Research Associates, Montebello, California, United States
πΊπΈCancer Research Network Inc, Plantation, Florida, United States
πΊπΈCalifornia Cancer Care Inc, Greenbrae, California, United States
A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies
- Conditions
- NeoplasmsMetastases, Neoplasm
- First Posted Date
- 2002-10-03
- Last Posted Date
- 2016-11-25
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT00046423
- Locations
- πΊπΈ
Abraxis Bioscience, Inc., Durham, North Carolina, United States